Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

The Irish biopharmaceutical company plans to use the funds for general corporate purposes.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

US-based drug discovery company LifeMine Therapeutics has secured $55m in a series A funding round led by WuXi Healthcare Ventures.

LifeMine plans to use the funds towards the development of innovative drugs.

Aldeyra Therapeutics has announced an underwritten public offering of three million shares of its common stock priced at $7.25 a share to raise $25m in total.

The US-based biotechnology company plans to use the funds towards the development of ADX-102 and other product candidates.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"US-based drug discovery company LifeMine Therapeutics has secured $55m in a series A funding round led by WuXi Healthcare Ventures."

Berkeley Lights has formed a partnership with Bayer to enable the latter to use its Beacon platform in drug development process.

The Beacon platform helps in accelerating cell line development and antibody discovery. It will help in enhancing Bayer’s drug discovery and development activities.

Berkeley Lights is a US-based provider of breakthrough platforms for bio-pharmaceutical processes.

Rodin Therapeutics has secured $27m in a venture financing round led by Atlas Venture.

The US-based novel therapeutics developer plans to use the funds towards the development of innovative drugs targeting neurological disorders.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact